Fitzgerald Joseph Michael 4

What Happened
Joseph Michael Fitzgerald, EVP & Group President, Cardiology at Boston Scientific (BSX), exercised/conversion of derivative awards and received new equity awards on Feb 12, 2026. He converted 3,462 derivative units into common stock and had 1,612 shares withheld to satisfy tax withholding (1,612 x $74.12 = $119,481). In addition, he was granted restricted stock units (RSUs) of 18,550 shares and 43,776 shares (total 62,326 RSUs) and received an option grant that vests over four years.

Key Details

• Transaction date: 2026-02-12; Form 4 filed 2026-02-17 (5 days after the transaction; typically Form 4 is due within two business days, so this appears late).
• Exercise/conversion: 3,462 derivative units converted to common stock (reported at $0 per share).
• Tax withholding: 1,612 shares were withheld/disposed to cover taxes at $74.12 per share, totaling $119,481 (transaction code F).
• Grants/awards: RSUs of 18,550 shares (F3) and 43,776 shares (F4) — total 62,326 RSUs; also an option grant that vests in four equal annual installments beginning Feb 12, 2027 (F5).
• Shares owned after the transaction: not specified in the provided filing data.
• Notable footnotes: F1 explains each RSU equals one share at settlement; F2 notes the reporting person disclaims beneficial ownership of shares held by his child; F3–F5 describe vesting schedules for the RSUs and option grant.
• Filing timeliness: filed Feb 17 for Feb 12 transactions — appears to be a late filing.

Context

• The exercise/conversion combined with share withholding for taxes is a routine post-exercise tax payment (share withholding), not an open-market sale for investment purposes.
• The awards (RSUs and option grant) are compensation grants that vest over future years and do not represent an immediate market purchase.
• For retail investors: grants and exercises by executives are common compensation events; purchases are generally more indicative of a direct bullish signal than routine exercises or tax withholdings.